Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
15 août 2023 16h01 HE
|
Diffusion Pharmaceuticals Inc.
Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 ...
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
30 mars 2023 07h00 HE
|
Diffusion Pharmaceuticals Inc.
Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in...
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
16 déc. 2022 06h30 HE
|
Diffusion Pharmaceuticals Inc.
LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting New Director to be...
Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing
05 déc. 2022 06h30 HE
|
Diffusion Pharmaceuticals Inc.
Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion received bids from more than 15 companies...
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
14 nov. 2022 16h01 HE
|
Diffusion Pharmaceuticals Inc.
Announced Thorough Evaluation of a Range of Potential Strategic OpportunitiesContinued GBM Study Start-up ActivitiesEnded Quarter with $25.9 million in Cash, Cash Equivalents and Marketable Securities...
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
14 nov. 2022 06h30 HE
|
Diffusion Pharmaceuticals Inc.
Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of...
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
25 oct. 2022 06h30 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
11 août 2022 18h48 HE
|
Diffusion Pharmaceuticals Inc.
• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022• Reported Positive Effects in TSC Altitude Trial• Ended Quarter with $28.5 million in Cash, Cash...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
26 juil. 2022 07h30 HE
|
Diffusion Pharmaceuticals Inc.
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)...
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
23 juin 2022 07h30 HE
|
Diffusion Pharmaceuticals Inc.
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise intervalPositive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to...